点击上面“蓝字”关注我们!本文来源于健康凯歌;如果喜欢,欢迎在文末处点个“在看”,感谢您的支持!十年前,中国制药行业还在仿制药的红海中“血拼厮杀”。五年前,中国创新药才刚刚在国际舞台崭露头角。而就在前两天,信达生物与武田制药达成的114亿美元(折合人民币812亿元)天价交易,震惊了整个医药界。这家曾长期亏损的中国生物科技企业,不仅在2025年上半年实现了8.34亿元的净利润,彻底扭亏为盈,更一举...
Source Link点击上面“蓝字”关注我们!本文来源于健康凯歌;如果喜欢,欢迎在文末处点个“在看”,感谢您的支持!十年前,中国制药行业还在仿制药的红海中“血拼厮杀”。五年前,中国创新药才刚刚在国际舞台崭露头角。而就在前两天,信达生物与武田制药达成的114亿美元(折合人民币812亿元)天价交易,震惊了整个医药界。这家曾长期亏损的中国生物科技企业,不仅在2025年上半年实现了8.34亿元的净利润,彻底扭亏为盈,更一举...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.